"If that study successfully demonstrates a clinical benefit for PTX-100, the drug could advance directly into another study that could be suitable for registration.Compared to the usual large Phase 3 studies, a comparatively smaller trial might be all that’s needed to register the drug, Prescient says.Yatomi-Clarke says the company is pursuing the quickest route to market for PTX-100 by pursuing areas of unmet clinical need."
Has anybody else noticed this in the * article? Seems quite significant and that the market may have over-reacted about not reaching a phase 2+3 combined trial.
More than 1 way to skin a cat?
Ann: PTX-100 trial advances following successful Phase 1b, page-183
-
- There are more pages in this discussion • 224 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
-0.001(2.17%) |
Mkt cap ! $36.23M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.8¢ | 4.5¢ | $26.66K | 576.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 219999 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 114091 | 2 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PTX (ASX) Chart |